drugset / Trial / NCT02223260

Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age

NCT02223260

Phase 2 Completed 8 enrolled Boehringer Ingelheim
NaSingle-groupOpen-label

Summary

The aim of the study is to investigate the safety and tolerability of dabigatran etexilate solution in children aged less than 1 year, to demonstrate comparable PK/PD relationship to older children and adults and to confirm dabigatran etexilate dosing algorithm for children aged less than 1 year.

Timeline

Start
2014-09
Primary completion
2016-01
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran Unknown Oral